Rovax Tablets 10/80 mg
Rosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
MFDS item code 202006071 · Approved 2020.08.28
This product's status changed to Expired on 2025.08.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hyperlipidemia; treatment of hypertension and heart failure; inhibition of cardiovascular risk and atherosclerosis progression
This medication is used for patients who need to take both valsartan and rosuvastatin simultaneously. Valsartan is primarily used in the treatment of essential hypertension and heart failure, and is particularly suitable for patients with heart failure who cannot use ACE inhibitors. It also helps reduce the risk of death in patients with left ventricular dysfunction following myocardial infarction. Rosuvastatin improves hypercholesterolemia and dyslipidemia, and is used as an adjunct when dietary measures are insufficient. This medication delays the progression of atherosclerosis in patients with hypercholesterolemia and is effective in reducing the risk of cardiovascular disease. Overall, this medication is used to prevent and treat cardiovascular diseases through blood pressure control and cholesterol improvement.
This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect occurs gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further reduction in blood pressure is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. If a diuretic is administered concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; over the following several weeks, the dose should be increased according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to the LDL cholesterol level, treatment goal, and patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Do not administer this medicine to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
1. Essential hypertension: 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 2. Heart failure: 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential should use appropriate contraceptive measures before taking this medication and should not use it during pregnancy. Patients with severe liver or kidney impairment, a history of certain genetic diseases, or muscle disorders should safely avoid this medication. Elderly patients, patients with hyperkalemia, and patients with mildly impaired liver function should use this medication with caution and undergo regular liver enzyme tests. This medication can cause muscle pain, muscle weakness, and occasionally severe muscle damage known as rhabdomyolysis, so any muscle-related symptoms should prompt immediate consultation with a physician. Additionally, blood pressure may suddenly drop, leading to dizziness or fainting, so caution is advised when starting the medication or increasing the dosage. There may be interactions with other medications, so any current medications should be disclosed to a doctor or pharmacist. Breastfeeding women are advised not to take this medication unless absolutely necessary, in which case breastfeeding should be discontinued. It is not recommended for children or adolescents as safety and efficacy have not been established in this population. In case of overdose, there is no specific antidote, so immediate medical attention should be sought. This medication should be kept out of reach of children, and should not be transferred to another container.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase (AST, ALT) levels, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, decreased sensation, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unknown skin tumor-like condition, herpes zoster, herniated disc, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, worsening angina, auditory abnormalities, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain (low back pain), abdominal pain, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, renal function impairment, hyperkalemia, angioedema, syncope, vascular edema, erythema, pruritus, serum sickness, vasculitis, hepatitis, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased hematocrit, decreased hemoglobin, edema, weakness, insomnia, erythema, decreased libido, dizziness, constipation, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, interstitial lung disease, jaundice, Stevens-Johnson syndrome, eosinophilia, and systemic symptom accompanying drug reaction syndrome (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that does not allow light to penetrate. Additionally, it is important to maintain the drug's effectiveness by storing it in a cool, room temperature, specifically between 1 and 30 degrees Celsius.
Pink round film-coated tablets
30 tablets/box [(10/PTP) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Rosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.